These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 38717195)

  • 21. Intranasal SARS-CoV-2 Omicron variant vaccines elicit humoral and cellular mucosal immunity in female mice.
    Slamanig S; González-Domínguez I; Chang LA; Lemus N; Lai TY; Martínez JL; Singh G; Dolange V; Abdeljawad A; Kowdle S; Noureddine M; Warang P; Singh G; Lee B; García-Sastre A; Krammer F; Schotsaert M; Palese P; Sun W
    EBioMedicine; 2024 Jul; 105():105185. PubMed ID: 38848648
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SARS-CoV-2 mRNA Vaccines Elicit Different Responses in Immunologically Naïve and Pre-Immune Humans.
    Forgacs D; Jang H; Abreu RB; Hanley HB; Gattiker JL; Jefferson AM; Ross TM
    Front Immunol; 2021; 12():728021. PubMed ID: 34646267
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis.
    Strengert M; Becker M; Ramos GM; Dulovic A; Gruber J; Juengling J; Lürken K; Beigel A; Wrenger E; Lonnemann G; Cossmann A; Stankov MV; Dopfer-Jablonka A; Kaiser PD; Traenkle B; Rothbauer U; Krause G; Schneiderhan-Marra N; Behrens GMN
    EBioMedicine; 2021 Aug; 70():103524. PubMed ID: 34391096
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses.
    Tauzin A; Gong SY; Beaudoin-Bussières G; Vézina D; Gasser R; Nault L; Marchitto L; Benlarbi M; Chatterjee D; Nayrac M; Laumaea A; Prévost J; Boutin M; Sannier G; Nicolas A; Bourassa C; Gendron-Lepage G; Medjahed H; Goyette G; Bo Y; Perreault J; Gokool L; Morrisseau C; Arlotto P; Bazin R; Dubé M; De Serres G; Brousseau N; Richard J; Rovito R; Côté M; Tremblay C; Marchetti GC; Duerr R; Martel-Laferrière V; Kaufmann DE; Finzi A
    Cell Host Microbe; 2022 Jan; 30(1):97-109.e5. PubMed ID: 34953513
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparable antibody levels in heterologous and homologous mRNA COVID-19 vaccination, with superior neutralizing and IgA antibody responses in mRNA homologous boosting.
    Younes S; Nicolai E; Younes N; Pieri M; Bernardini S; Nizamuddin PB; Al-Sadeq DW; Daas HI; Ismail A; Yassine HM; Abu-Raddad LJ; Nasrallah GK
    Vaccine; 2024 Oct; 42(23):126042. PubMed ID: 38845303
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity of COVID-19 booster vaccination in IEI patients and their one year clinical follow-up after start of the COVID-19 vaccination program.
    van Leeuwen LPM; Grobben M; GeurtsvanKessel CH; Ellerbroek PM; de Bree GJ; Potjewijd J; Rutgers A; Jolink H; van de Veerdonk FL; van Gils MJ; de Vries RD; Dalm VASH;
    Front Immunol; 2024; 15():1390022. PubMed ID: 38698851
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibody and T-Cell Response to Bivalent Booster SARS-CoV-2 Vaccines in People With Compromised Immune Function: COVERALL-3 Study.
    Amstutz A; Chammartin F; Audigé A; Eichenberger AL; Braun DL; Amico P; Stoeckle MP; Hasse B; Papadimitriou-Olivgeris M; Manuel O; Bongard C; Schuurmans MM; Hage R; Damm D; Tamm M; Mueller NJ; Rauch A; Günthard HF; Koller MT; Schönenberger CM; Griessbach A; Labhardt ND; Kouyos RD; Trkola A; Kusejko K; Bucher HC; Abela IA; Briel M; Speich B; ;
    J Infect Dis; 2024 Oct; 230(4):e847-e859. PubMed ID: 38848312
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and cross-variant immunogenicity of a three-dose COVID-19 mRNA vaccine regimen in kidney transplant recipients.
    Massa F; Cremoni M; Gérard A; Grabsi H; Rogier L; Blois M; Couzin C; Hassen NB; Rouleau M; Barbosa S; Martinuzzi E; Fayada J; Bernard G; Favre G; Hofman P; Esnault VLM; Czerkinsky C; Seitz-Polski B; Glaichenhaus N; Sicard A
    EBioMedicine; 2021 Nov; 73():103679. PubMed ID: 34763205
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of SARS-CoV-2 Antibody Response 4 Weeks After Homologous vs Heterologous Third Vaccine Dose in Kidney Transplant Recipients: A Randomized Clinical Trial.
    Reindl-Schwaighofer R; Heinzel A; Mayrdorfer M; Jabbour R; Hofbauer TM; Merrelaar A; Eder M; Regele F; Doberer K; Spechtl P; Aschauer C; Koblischke M; Paschen C; Eskandary F; Hu K; Öhler B; Bhandal A; Kleibenböck S; Jagoditsch RI; Reiskopf B; Heger F; Bond G; Böhmig GA; Strassl R; Weseslindtner L; Indra A; Aberle JH; Binder M; Oberbauer R
    JAMA Intern Med; 2022 Feb; 182(2):165-171. PubMed ID: 34928302
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Poor humoral and T-cell response to two-dose SARS-CoV-2 messenger RNA vaccine BNT162b2 in cardiothoracic transplant recipients.
    Schramm R; Costard-Jäckle A; Rivinius R; Fischer B; Müller B; Boeken U; Haneya A; Provaznik Z; Knabbe C; Gummert J
    Clin Res Cardiol; 2021 Aug; 110(8):1142-1149. PubMed ID: 34241676
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Co-administration of recombinant BCG and SARS-CoV-2 proteins leads to robust antiviral immunity.
    Ramírez MA; Loaiza RA; Martínez-Balboa Y; Bruneau N; Ramírez E; González PA; Bueno SM; Kalergis AM
    Vaccine; 2024 Oct; 42(23):126203. PubMed ID: 39178767
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans.
    Alter G; Yu J; Liu J; Chandrashekar A; Borducchi EN; Tostanoski LH; McMahan K; Jacob-Dolan C; Martinez DR; Chang A; Anioke T; Lifton M; Nkolola J; Stephenson KE; Atyeo C; Shin S; Fields P; Kaplan I; Robins H; Amanat F; Krammer F; Baric RS; Le Gars M; Sadoff J; de Groot AM; Heerwegh D; Struyf F; Douoguih M; van Hoof J; Schuitemaker H; Barouch DH
    Nature; 2021 Aug; 596(7871):268-272. PubMed ID: 34107529
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Impact of Time between Booster Doses on Humoral Immune Response in Solid Organ Transplant Recipients Vaccinated with BNT162b2 Vaccines.
    Hamm SR; Loft JA; Pérez-Alós L; Heftdal LD; Hansen CB; Møller DL; Pries-Heje MM; Hasselbalch RB; Fogh K; Hald A; Ostrowski SR; Frikke-Schmidt R; Sørensen E; Hilsted L; Bundgaard H; Garred P; Iversen K; Perch M; Sørensen SS; Rasmussen A; Sabin CA; Nielsen SD
    Viruses; 2024 May; 16(6):. PubMed ID: 38932153
    [TBL] [Abstract][Full Text] [Related]  

  • 34. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants.
    Wang Z; Schmidt F; Weisblum Y; Muecksch F; Barnes CO; Finkin S; Schaefer-Babajew D; Cipolla M; Gaebler C; Lieberman JA; Oliveira TY; Yang Z; Abernathy ME; Huey-Tubman KE; Hurley A; Turroja M; West KA; Gordon K; Millard KG; Ramos V; Da Silva J; Xu J; Colbert RA; Patel R; Dizon J; Unson-O'Brien C; Shimeliovich I; Gazumyan A; Caskey M; Bjorkman PJ; Casellas R; Hatziioannou T; Bieniasz PD; Nussenzweig MC
    Nature; 2021 Apr; 592(7855):616-622. PubMed ID: 33567448
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Augmented humoral response to third and fourth dose of SARS-CoV-2 mRNA vaccines in lung transplant recipients.
    Kawana S; Sugimoto S; Matsubara K; Choshi H; Tanaka S; Ishihara M; Habu T; Hashimoto K; Suzawa K; Shien K; Miyoshi K; Okazaki M; Nakayama M; Toyooka S
    Respir Investig; 2024 Sep; 62(5):804-810. PubMed ID: 39002293
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of the induction of humoral and cellular immunity by third vaccination for SARS-CoV-2.
    Murayama G; Kusaoi M; Horiuchi Y; Tabe Y; Naito T; Ito S; Yamaji K; Tamura N
    J Infect Chemother; 2024 Oct; 30(10):1021-1027. PubMed ID: 38570139
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Profiling Humoral Immunity After Mixing and Matching COVID-19 Vaccines Using SARS-CoV-2 Variant Protein Microarrays.
    Kuo HC; Kuo KC; Du PX; Keskin BB; Su WY; Ho TS; Tsai PS; Pau CH; Shih HC; Huang YH; Weng KP; Syu GD
    Mol Cell Proteomics; 2023 Apr; 22(4):100507. PubMed ID: 36787877
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women.
    Collier AY; McMahan K; Yu J; Tostanoski LH; Aguayo R; Ansel J; Chandrashekar A; Patel S; Apraku Bondzie E; Sellers D; Barrett J; Sanborn O; Wan H; Chang A; Anioke T; Nkolola J; Bradshaw C; Jacob-Dolan C; Feldman J; Gebre M; Borducchi EN; Liu J; Schmidt AG; Suscovich T; Linde C; Alter G; Hacker MR; Barouch DH
    JAMA; 2021 Jun; 325(23):2370-2380. PubMed ID: 33983379
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neutralization of SARS-CoV-2 Variants in Transplant Recipients After Two and Three Doses of mRNA-1273 Vaccine : Secondary Analysis of a Randomized Trial.
    Kumar D; Ferreira VH; Hall VG; Hu Q; Samson R; Ku T; Ierullo M; Majchrzak-Kita B; Tomlinson G; Gingras AC; Humar A
    Ann Intern Med; 2022 Feb; 175(2):226-233. PubMed ID: 34807716
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune response against the SARS-CoV-2 spike protein in cancer patients after COVID-19 vaccination during the Omicron wave: a prospective study.
    Muñoz-Gómez MJ; Ryan P; Quero-Delgado M; Martin-Vicente M; Cuevas G; Valencia J; Jiménez E; Blanca-López N; Lara-Álvarez MÁ; Hernández-Rivas JÁ; Redondo G; Mas V; Sepúlveda-Crespo D; Vázquez M; Torres-Macho J; Martínez I; Resino S
    J Infect Public Health; 2024 Jul; 17(7):102473. PubMed ID: 38865774
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.